Vorinostat

Generic Name
Vorinostat
Brand Names
Zolinza
Drug Type
Small Molecule
Chemical Formula
C14H20N2O3
CAS Number
149647-78-9
Unique Ingredient Identifier
58IFB293JI
Background

Vorinostat (rINN) or suberoylanilide hydroxamic acid (SAHA), is a drug currently under investigation for the treatment of cutaneous T cell lymphoma (CTCL), a type of skin cancer, to be used when the disease persists, gets worse, or comes back during or after treatment with other medicines. It is the first in a new class of agents known as histone deacetylase...

Indication

用于治疗加重、持续和复发或用两种全身性药物治疗后无效的T细胞淋巴瘤(CTCL, 一种非霍奇金淋巴瘤)。

Associated Conditions
Cutaneous T-Cell Lymphoma Recurrent, Persistent Cutaneous T-Cell Lymphoma, Progressive Cutaneous T-cell lymphoma
Associated Therapies
-
Clinical Trials
Related News

Vorinostat and 177Lu-PSMA-617 for the Treatment of PSMA-Low Metastatic Castration-Resistant Prostate Cancer

First Posted Date
2023-11-24
Last Posted Date
2024-08-23
Lead Sponsor
University of Washington
Target Recruit Count
15
Registration Number
NCT06145633
Locations
🇺🇸

Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States

TINI 2: Total Therapy for Infants With Acute Lymphoblastic Leukemia II

First Posted Date
2023-05-08
Last Posted Date
2024-11-25
Lead Sponsor
Tanja Andrea Gruber
Target Recruit Count
90
Registration Number
NCT05848687
Locations
🇺🇸

Phoenix Children's Hospital, Phoenix, Arizona, United States

🇺🇸

Arkansas Children's Hospital, Little Rock, Arkansas, United States

🇺🇸

Children's Hospital Los Angeles, Los Angeles, California, United States

and more 22 locations

Ph1 Study of FT538 Alone and With Vorinostat for Persistent Low-Level HIV Viremia

First Posted Date
2023-01-26
Last Posted Date
2024-02-26
Lead Sponsor
Masonic Cancer Center, University of Minnesota
Registration Number
NCT05700630
Locations
🇺🇸

Masonic Cancer Center at University of Minnesota, Minneapolis, Minnesota, United States

Vorinostat in Combination With Chemoradiation in Locally Advanced HPV Negative HNSCC

First Posted Date
2022-11-08
Last Posted Date
2024-12-20
Lead Sponsor
Kyunghee Burkitt, DO, PhD
Target Recruit Count
21
Registration Number
NCT05608369
Locations
🇺🇸

University Hospitals Cleveland Medical Center, Case Comprehensive Cancer Center, Cleveland, Ohio, United States

Venetoclax to Augment Epigenetic Modification and Chemotherapy

First Posted Date
2022-04-07
Last Posted Date
2024-11-26
Lead Sponsor
Medical College of Wisconsin
Target Recruit Count
40
Registration Number
NCT05317403
Locations
🇺🇸

Children's Wisconsin, Milwaukee, Wisconsin, United States

Effect of Vorinostat on ACTH Producing Pituitary Adenomas in Cushing s Disease

Phase 2
Recruiting
Conditions
Cushing's Disease
Interventions
Drug: Vorinostat
First Posted Date
2020-04-09
Last Posted Date
2024-12-20
Lead Sponsor
National Institute of Neurological Disorders and Stroke (NINDS)
Target Recruit Count
22
Registration Number
NCT04339751
Locations
🇺🇸

National Institutes of Health Clinical Center, Bethesda, Maryland, United States

Vorinostat in Combination With Chemotherapy in Relapsed/Refractory Solid Tumors and CNS Malignancies

First Posted Date
2020-03-16
Last Posted Date
2023-10-26
Lead Sponsor
New York Medical College
Target Recruit Count
30
Registration Number
NCT04308330
Locations
🇺🇸

New York Medical College, Valhalla, New York, United States

Vorinostat and Combination Chemotherapy Before Donor Stem Cell Transplantation for the Treatment of Relapsed Aggressive B-cell or T-cell Non-Hodgkin Lymphoma

First Posted Date
2020-01-07
Last Posted Date
2024-01-12
Lead Sponsor
M.D. Anderson Cancer Center
Registration Number
NCT04220008

Pembrolizumab and Tamoxifen With or Without Vorinostat for the Treatment of Estrogen Receptor Positive Breast Cancer

First Posted Date
2019-12-09
Last Posted Date
2023-08-31
Lead Sponsor
University of California, San Francisco
Target Recruit Count
1
Registration Number
NCT04190056
Locations
🇺🇸

University of California, San Francisco, San Francisco, California, United States

Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial

Phase 1
Terminated
Conditions
Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive
Anatomic Stage IV Breast Cancer AJCC v8
Anemia
Ann Arbor Stage III Hodgkin Lymphoma
Ann Arbor Stage III Non-Hodgkin Lymphoma
Ann Arbor Stage IV Hodgkin Lymphoma
Ann Arbor Stage IV Non-Hodgkin Lymphoma
Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative
Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive
Castration-Resistant Prostate Carcinoma
Interventions
Drug: Abemaciclib
Drug: Abiraterone
Drug: Afatinib
Biological: Bevacizumab
Drug: Bicalutamide
Procedure: Biospecimen Collection
Drug: Bortezomib
Drug: Cabazitaxel
Drug: Cabozantinib
Drug: Capecitabine
Drug: Carboplatin
Drug: Celecoxib
Drug: Cobimetinib
Drug: Copanlisib
Drug: Dabrafenib
Drug: Dacomitinib
Drug: Darolutamide
Drug: Dasatinib
Drug: Doxorubicin
Biological: Durvalumab
Drug: Enasidenib
Drug: Entrectinib
Drug: Enzalutamide
Drug: Erlotinib
Drug: Everolimus
Drug: Fluorouracil
Drug: Idelalisib
Drug: Imatinib
Biological: Ipilimumab
Drug: Lenvatinib
Drug: Leucovorin
Drug: Lorlatinib
Drug: Losartan
Drug: Nab-paclitaxel
Drug: Neratinib
Biological: Nivolumab
Drug: Olaparib
Drug: Oxaliplatin
Drug: Palbociclib
Drug: Panobinostat
Biological: Pembrolizumab
Biological: Pertuzumab
Drug: Ponatinib
Other: Quality-of-Life Assessment
Drug: Regorafenib
Drug: Ruxolitinib
Drug: Sirolimus
Drug: Sorafenib
Drug: Sunitinib
Drug: Trametinib
Biological: Trastuzumab Emtansine
Drug: Tretinoin
Drug: Vemurafenib
Drug: Venetoclax
Drug: Vismodegib
Drug: Vorinostat
First Posted Date
2019-03-18
Last Posted Date
2024-03-04
Lead Sponsor
OHSU Knight Cancer Institute
Target Recruit Count
2
Registration Number
NCT03878524
Locations
🇺🇸

OHSU Knight Cancer Institute, Portland, Oregon, United States

© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy